Abologix

Abologix is a biopharmaceutical company based in Geneva, Switzerland. The company is a spin out from the laboratories of Prof. Beat Imhof and Thomas Matthes at the University of Geneva and the Geneva University Hospitals. The company is developing two monoclonal antibodies that selectively block two novel pharmacological targets. Several oncological medical indications are being pursued.